Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03265431 · ClinicalTrials.gov registry record · Phase 2

Evaluation of PET/MR in Patients Selected for Ablation Therapy

A Phase 2 study of Arrhythmias, Cardiac, sponsored by Massachusetts General Hospital.

Active
Registry status
Phase 2
Development phase
34
Enrollment target
1
Study location

NCT03265431: Active Phase 2 study of Arrhythmias, Cardiac, sponsored by Massachusetts General Hospital.

NCT03265431 is a Phase 2 study of Arrhythmias, Cardiac that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 34 participants, below the 560-participant average among 17 other Arrhythmias, Cardiac trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03265431, a Phase 2 study of Arrhythmias, Cardiac, is active but no longer recruiting, sponsored by Massachusetts General Hospital.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
34 participants
Enrollment target
1
Study location

Study Summary

This study is performed to assess if PET-MR imaging can improve treatment of patients with irregular heart rate and heart failure. Heart failure occurs when the heart muscle is too weak to do his work correctly. Irregular heart rate can be related to numerous diseases. One category of irregular heart rate is called ventricular arrhythmia. It is often seen in patients who have had a heart attack. This type of arrhythmia can be dangerous and can cause sudden death. To prevent these arrhythmias, doctors can perform procedures that burn the source of arrhythmia in the heart muscle. This is called ablation. Unfortunately, ablation does not fix the problem in 100% of patients and some will still have the arrhythmia requiring repeated procedure. The purpose of this study is to find new ways of guiding the doctors performing ablation, hoping to improve the success rate of the procedure.

Primary Outcome

Establish imaging patterns allowing prediction of VT ablation failure

Conditions Studied

Interventions

  • DRUG 18F-TPP

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2017-07-14
Est. Completion 2027-06-30
Phase Phase 2
Massachusetts General Hospital

2,032 total trials

What the registry record for NCT03265431 still lists

NCT03265431 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 560-participant average among 17 other Arrhythmias, Cardiac trials with a reported enrollment target (94% lower).

The record links to 1 condition, with Arrhythmias, Cardiac appearing as the primary indexed condition, and to 1 intervention - of which 18F-TPP is the first listed.

NCT03265431 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03265431 about?

NCT03265431 is a clinical study titled "Evaluation of PET/MR in Patients Selected for Ablation Therapy". This study is performed to assess if PET-MR imaging can improve treatment of patients with irregular heart rate and heart failure. Heart failure occurs when the heart muscle is too weak to do his work correctly. Irregular heart rate can be related to numerous diseases. One category of irregular hear...

What is the current status of trial NCT03265431?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2017-07-14. Estimated completion is 2027-06-30.

What conditions does trial NCT03265431 study?

This clinical trial studies the following conditions: Arrhythmias, Cardiac.

What interventions are being tested in trial NCT03265431?

The interventions under investigation include: 18F-TPP (DRUG).

Who is sponsoring clinical trial NCT03265431?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03265431 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Arrhythmias, Cardiac

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03265431's enrollment target sits among peer trials

34 16th of 17 higher than 2 of 17 other Arrhythmias, Cardiac trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Arrhythmias, Cardiac trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02897063 · 34 participants · Phase 1

    Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

  • NCT03906617 · 34 participants · Phase 4

    Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine

  • NCT03992378 · 34 participants · NA

    Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis

  • NCT04047849 · 34 participants · Phase 4

    Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03265431, the US trial registry maintained by the National Library of Medicine. NCT03265431 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.